Seeking Alpha

Neoprobe (NEOP -10.2%) fell sharply in afternoon trading on rumors an application for its...

Neoprobe (NEOP -10.2%) fell sharply in afternoon trading on rumors an application for its Lymphoseek cancer-detection drug was rejected. However, shares are up 5.8% AH after a spokesperson says Neoprobe isn't aware of any news about its application, which the FDA is expected to decide upon by Oct. 24.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|